XML 70 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details) - EUR (€)
€ in Thousands
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue from collaboration and licensing agreements € 8,293 € 35,344
Proceeds from collaboration and licensing agreements    
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue from collaboration and licensing agreements 7,396 34,728
Monalizumab agreement (AstraZeneca)    
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue from collaboration and licensing agreements 2,994 9,503
Agreement with Sanofi, 2016    
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue from collaboration and licensing agreements 4,000 2,000
Agreement with Sanofi, 2022 - ANKET IPH62    
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue from collaboration and licensing agreements 199 18,672
Agreement With Sanofi 2022 - ANKET IPH67    
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue from collaboration and licensing agreements 203 0
Takeda agreement    
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue from collaboration and licensing agreements 0 4,553
Invoicing of R&D costs (IPH5201 agreement)    
Disclosure of disaggregation of revenue from contracts with customers [line items]    
Revenue from collaboration and licensing agreements € 897 € 616